Discover a study where researchers have discovered a myeloid-derived antigen-presenting cells population essential for peripherally induced regulatory T cells.

T-cell activation involves two phases, enabling a more precise immune response. This insight may boost cancer immunotherapy ...

Our body's own defense system not only clears away bacteria and viruses, it can also fight cancer. However, not all tumor ...

Cellecta, Inc., Mountain View, CA.

Roche’s Genentech has inked a deal with Repertoire Immune Medicines aimed at discovering and developing T-cell-targeted ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

We have developed a versatile method for generating tolerogenic antigen-presenting cells in vivo by delivering mRNA encoding PDL1 via lipid nanoparticles. These tolerogenic antigen-presenting ...

Novita Pharmaceuticals, Inc. ("Novita"), a privately held, clinical-stage pharmaceutical company dedicated to developing novel cancer drugs through its proprietary fascin inhibitor technology, today ...